Browse News
Filter News
Found 7,809 articles
-
Cancer Gene Therapy Industry is Rising Rapidly Up to USD 18.11 Bn by 2033
4/18/2024
The global cancer gene therapy market size was accounted for USD 2.95 billion in 2023 and it is increasing around USD 18.11 billion by 2033
-
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
4/18/2024
CureVac N.V. will report financial results, and provide business updates for the fourth quarter and full-year 2023 on Wednesday, April 24, 2024.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
GSK’s antibiotic eliminated the bacterial cause of gonorrhea in 92.6% of patients in a Phase III study, while its Shingrix vaccine’s efficacy in shingles remained above 70% over 11 years of follow up.
-
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
4/16/2024
Innovent Biologics, Inc. announces the appointment of Dr. Nageatte Ibrahim, a world-famous Oncology Clinical Development Leader in the Pharmaceutical Industry, as the Oncology CMO.
-
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
4/16/2024
CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), and The University of Texas MD Anderson Cancer Center today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
-
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
4/16/2024
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer.
-
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
4/15/2024
Applied Therapeutics, Inc. announced the appointment of Dale Hooks as Chief Commercial Officer, replacing Adam Hansard, effective immediately.
-
The FDA on Thursday approved the label expansion of AstraZeneca’s Fasenra as an add-on maintenance treatment for severe eosinophilic asthma in patients six to 11 years of age.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Small Cell Lung Cancer Therapeutics Market Size is Expanding at USD 16.33 Billion by 2032
4/11/2024
The small cell lung cancer therapeutics market size was valued at 5.75 billion in 2023 and is anticipated to reach around 16.33 billion by 2032, expanding at a CAGR of 12.3% from 2023 to 2032.
-
ProPharma Announces Changes to Its Executive Leadership Team
4/11/2024
ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners is pleased to announce that it has welcomed Kirk Wroblewski as its new Chief Information Officer and Andrew Shaw as General Counsel.
-
World Leaders, Global CEOs From Tech, Finance and Health Industries, to Join Leading Experts in Economics, Academia, Government, and Philanthropy to Address Pressing Global Issues at Milken Institute 2024 Global Conference
4/11/2024
The Milken Institute announced its program agenda and initial list of distinguished speakers for its 2024 Global Conference, taking place from May 5 – 8 at The Beverly Hilton in Los Angeles, CA.
-
Pfizer’s respiratory syncytial virus vaccine Abrysvo is just as effective in younger adults aged 18 to 59 years as it is in the shot’s currently approved population of 60 years of age and older.
-
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
4/9/2024
SCYNEXIS, Inc. (NASDAQ: SCYX) today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain from April 27-30, 2024.
-
OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann
4/8/2024
OMass Therapeutics, a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, announces the appointment of Sarah Teichmann PhD, FMedSci, FRS to its Scientific Advisory Board, effective immediately.
-
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
4/8/2024
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV.
-
Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort
4/8/2024
Clover Biopharmaceuticals, Ltd. announced positive preliminary immunogenicity and safety data in the initial young adult cohort from its Phase I trial evaluating SCB-1019 – the company's bivalent RSV prefusion-stabilized F -Trimer subunit vaccine candidate – which is based on Clover's Trimer-Tag vaccine technology platform.
-
Actuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting
4/8/2024
Actuate Therapeutics, Inc. announced today two poster presentations from scientific collaborators at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, California.
-
Sanofi has in principle reached a settlement related to its discontinued heartburn drug Zantac, though the French pharma did not disclose the financial terms of the deal.